Literature DB >> 11710736

Antiangiogenic and antivascular therapy for cancer.

G Taraboletti1, B Margosio.   

Abstract

The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation of vessels, and antivascular compounds, targeted to the existing tumor vasculature. Following promising preclinical studies, antiangiogenic drugs have rapidly gained access to clinical trials.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11710736     DOI： 10.1016/s1471-4892(01)00065-0

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  15 in total

1.  FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice.

Authors:  Yunping Luo; Dorothy Markowitz; Rong Xiang; He Zhou; Ralph A Reisfeld
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

2.  Mechanism of inhibition of ascites tumor growth in mice by curcumin is mediated by NF-kB and caspase activated DNase.

Authors:  Madesh Belakavadi; Bharathi P Salimath
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

3.  Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice.

Authors:  Yasmine S Touil; Johanne Seguin; Daniel Scherman; Guy G Chabot
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-11       Impact factor: 3.333

4.  An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.

Authors:  Matthew M Seavey; Paulo C Maciag; Nada Al-Rawi; Duane Sewell; Yvonne Paterson
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

5.  Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization.

Authors:  Yasmine S Touil; Arlette Fellous; Daniel Scherman; Guy G Chabot
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

6.  The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.

Authors:  Marta Cesca; Roberta Frapolli; Alexander Berndt; Valentina Scarlato; Petra Richter; Hartwig Kosmehl; Maurizio D'Incalci; Anderson J Ryan; Raffaella Giavazzi
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

7.  Absorption, distribution and excretion of ¹⁴C-probimane in mice bearing lewis lung carcinoma.

Authors:  Da-Yong Lu; Rui-Ting Chen; Ting-Ren Lu; Hong-Ying Wu; Rong-Xin Qu; Jin-Yu Che; Bin Xu
Journal:  Sci Pharm       Date:  2010-06-15

8.  Different spontaneous pulmonary metastasis inhibitions against lewis lung carcinoma in mice by bisdioxopiperazine compounds of different treatment schedules.

Authors:  Da-Yong Lu; Fu-Geng Wu; Zu-Ming Zhen; Ting-Ren Lu; Hong-Ying Wu; Jin-Yu Che; Bin Xu
Journal:  Sci Pharm       Date:  2009-12-29

9.  Vaccines targeting the neovasculature of tumors.

Authors:  Agata Matejuk; Qixin Leng; Szu-Ting Chou; Archibald J Mixson
Journal:  Vasc Cell       Date:  2011-03-08

10.  Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines.

Authors:  Da Yong Lu; Min Huang; Cheng Hui Xu; Wei Yi Yang; Chao Xin Hu; Li Ping Lin; Lin Jiang Tong; Mei Hong Li; Wei Lu; Xiong Wen Zhang; Jian Ding
Journal:  BMC Pharmacol       Date:  2005-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.